Author(s):
Subashini Rajaram, Rajendran Natham
Email(s):
subababu.r@gmail.com
DOI:
10.5958/0974-360X.2020.01034.3 
Address:
Subashini Rajaram1*, Rajendran Natham2
1Department of Pharmaceutics and Research, Swamy Vivekanandha College of Pharmacy, Tiruchengode, Namakkal - 637205, Tamilnadu, India.
2The Tamilnadu DR. M. G. R. Medical University, Chennai.
*Corresponding Author
Published In:
Volume - 13,
Issue - 12,
Year - 2020
ABSTRACT:
Bioavailability of rifampicin (RIF) remains a concern for effective management of tuberculosis (TB). Previous study shows that ascorbic acid (ASC) inhibits degradation of RIF to insoluble and poorly absorbed 3- formyl rifampicin in the acid environment of the stomach and improves its bioavailability and also protects RIF against isoniazid (INH) induced degradation in the acidic environment. ASC is also used in dissolution medium and in plasma sample to stabilize RIF against its degradation. Additionally ASC is recommended in clinical practice along with fixed dose combination (FDC) products to control the growth of Micobacterium tuberculosis (M.Tb), Nanoparticulate delivery is one of the approaches currently employed to drugs that show poor bioavailability. The present study attempted to examine whether ASC can influence bioavailability of RIF nanoparticles (NPs) prepared by ionic gelation method with chitosan (CS) as polymer in the presence of INH in the acidic environment of the stomach, The Nps were evaluated for in vitro dissolution and diffusion and in vivo bioavailability in the presence of INH and the results were compared with the control. The results demonstrated enhanced dissolution and diffusion with improved Cmax and (AUC0-12, 0-8) of RIF NPs as compared to control and conclude that ASC is beneficial to improve the bioavailability of RIF NPs that can control TB effectively.
Cite this article:
Subashini Rajaram, Rajendran Natham. Enhancement of Rifampicin Bioavailability by Immune Enhancing Nutrient (Ascorbic Acid) as Chitosan Nanoparticles for Tuberculosis Therapy. Research J. Pharm. and Tech. 2020; 13(12):5924-5928. doi: 10.5958/0974-360X.2020.01034.3
Cite(Electronic):
Subashini Rajaram, Rajendran Natham. Enhancement of Rifampicin Bioavailability by Immune Enhancing Nutrient (Ascorbic Acid) as Chitosan Nanoparticles for Tuberculosis Therapy. Research J. Pharm. and Tech. 2020; 13(12):5924-5928. doi: 10.5958/0974-360X.2020.01034.3 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-12-49
REFERENCES:
1. World Health Organization. Tuberculosis, 2018, http:// www.who.int/news-room/fact-sheets/detail/tuberculosis
2. Alimuddin Zumla, Mario Raviglione, Richard Hafner, and C. Fordham von Reyn. 2013. Current concepts Tuberculosis. The new England Journal of Medicine. 2013; 368: 745-55.
3. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB2014.08. Geneva, World Health Organization.
4. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull WHO. 2001; 79: 61-79.
5. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm. 2001; 228: 53-67.
6. Laing R, Fourie B, Ellard G, Sesay M, Spinaci S, Blomberg B, Bryant D. Fixed-dose combination tablets for the treatment of tuberculosis. In Report of an informal meeting held in Geneva, Tuesday, 27 April 1999. World Health Organization, Geneva, WHO/CDS/CPC/TB/99.267.
7. World Health Organization: Stop TB: Stop TB. 2002. Frequently asked questions about the 4-drug fixed-dose combination tablet recommended by the World Health Organization for treating tuberculosis. Geneva: WHO, September WHO/CDS/STB/ 2002.18; 2002.
8. Levine M, Conry Cantilena C, Wany Y, Weleh RW. 1996. Vitamin C pharmacokinetic in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. 93: 3704-09.
9. Gaurav KS, Puspha G, Gupta UD, Jain NK. 2010. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 2010; 385: 43-49.
10. Shishoo CJ, Shah SA, Rathod S, Savale SS. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 1999; 190: 109-123.
11. Lifeng QI, Zirong XU, Xia J, Caihong H. Preparation and anti-bacterial activity of chitosan nanoparticles. Carbohydrates Res. 2004; 339: 2693-2700.
12. LisaClaire, DT, Viness, P, and Michael, PD. Tuberculosis chemotherapy: Current drug delivery approaches. Respiratory. Res. 2006; 7: 1-18.
13. Calvo, P, Remunan, LC, Vila-J, JL, Alonso, MJ. 1997. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polymer. Scienc. 1997; 63: 125-32.
14. Bhavika M, Nishi S, Saranjit S. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin, J. Pharm. Biomed. Anal. 2003; 31: 607–12.